Time‐resolved contrast‐enhanced three‐dimensional pulmonary MR‐angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine

To compare contrast characteristics and image quality of 1.0 M gadobutrol with 0.5 M Gd‐DTPA for time‐resolved three‐dimensional pulmonary magnetic resonance angiography (MRA).

[1]  M. Oudkerk,et al.  Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a prospective study , 2002, The Lancet.

[2]  Hiroto Hatabu,et al.  Time‐resolved contrast‐enhanced pulmonary MR angiography using sensitivity encoding (SENSE) , 2003, Journal of magnetic resonance imaging : JMRI.

[3]  W. Heindel,et al.  Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. , 2001, Radiology.

[4]  R Frayne,et al.  Time‐resolved contrast‐enhanced 3D MR angiography , 1996, Magnetic resonance in medicine.

[5]  J. Debatin,et al.  0.5 M Gd chelate (Magnevist®) versus 1.0 M Gd chelate (Gadovist®): Dose‐independent effect on image quality of pelvic three‐dimensional MR‐angiography , 2001, Journal of magnetic resonance imaging : JMRI.

[6]  M. Völk,et al.  Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. , 2001, Radiology.

[7]  A. Shetty,et al.  Contrast‐enhanced MRA in pre‐embolization assessment of a pulmonary arteriovenous malformation , 1997, Journal of magnetic resonance imaging : JMRI.

[8]  M. Knopp,et al.  [Multiphasic MR angiography as an intra-individual comparison between the contrast agents Gd-DTPA, Gd-BOPTA, and Gd-BT-DO3A]. , 2003, Der Radiologe.

[9]  C. Heussel,et al.  [Morphologic and functional assessment of vascular abnormalities of the pulmonary vasculature by breath-hold MR techniques]. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[10]  L R Schad,et al.  Separation of arteries and veins in 3D MR angiography using correlation analysis , 2000, Magnetic resonance in medicine.

[11]  H. Weinmann,et al.  Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. , 1995, European journal of radiology.

[12]  J. Debatin,et al.  Intraindividual Comparison of Gadopentetate Dimeglumine, Gadobenate Dimeglumine, and Gadobutrol for Pelvic 3D Magnetic Resonance Angiography , 2003, Investigative radiology.

[13]  P. Wielopolski,et al.  Three-dimensional MR imaging of the pulmonary vasculature: preliminary experience. , 1992, Radiology.

[14]  W. Heindel,et al.  Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol , 2002, European Radiology.

[15]  F. Floemer,et al.  Intraindividueller Vergleich dreier Kontrastmittel (Gd-DTPA, Gd-BOPTA und Gd-BT-DO3A) mit der multiphasischen MR-Angiographie , 2003, Der Radiologe.

[16]  H. Gudbjartsson,et al.  The rician distribution of noisy mri data , 1995, Magnetic resonance in medicine.

[17]  T. Vogl,et al.  Gadomer-17-enhanced 3D navigator-echo MR angiography of the pulmonary arteries in pigs , 2002, European Radiology.

[18]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[19]  P. Wielopolski.  Magnetic resonance pulmonary angiography. , 1999, Coronary artery disease.

[20]  Christina J. Herold,et al.  Pulmonary magnetic resonance angiography , 1999, European Radiology.

[21]  Gerhard Laub,et al.  Dynamic 3D MR angiography of the pulmonary arteries in under four seconds , 2001, Journal of magnetic resonance imaging : JMRI.

[22]  Michael Bock,et al.  High‐resolution pulmonary arterio‐ and venography using multiple‐bolus multiphase 3D‐gd‐mRA , 1999, Journal of magnetic resonance imaging : JMRI.

[23]  H. Weinmann,et al.  Pharmacokinetics, Dose Proportionality, and Tolerability of Gadobutrol after Single Intravenous Injection in Healthy Volunteers , 1994, Investigative radiology.

[24]  C. Fink,et al.  Pulmonary arteriovenous malformation and aortopulmonary collateral imaged by time resolved contrast enhanced magnetic resonance angiography , 2002, Heart.

[25]  J. Debatin,et al.  Optimization of contrast dosage for gadolinium-enhanced 3D MRA of the pulmonary and renal arteries. , 1998, Magnetic resonance imaging.